Chronic Lymphocytic Leukemia (CLL) treatment often leads to adverse drug reactions (ADRs) and drug-drug interactions (DDIs), significantly impacting patients’ quality of life (QoL). To address the challenges in managing ADRs/DDIs, the PEDRO platform was developed to enhance communication between healthcare professionals (HCPs) managing patients with CLL in real-world healthcare settings and experts with significant research profiles in CLL. This paper presents the PEDRO platform built to provide a secure, scalable, and user-friendly solution for peer-to-peer (P2P) support in ADR/DDI management.
PEDRO: A Peer-to-Peer Support Platform for Adverse Drug Reaction Management in Patients with CLL / Timamopoulos, C.; Chatzikonstantinou, T.; Panos, B.; Scarfo', L.; Ghia, P.; Kostas, S.; Anastasia, F.; Achilleas, C.; Alexandros, R.; Kalliopi, K.; Natsiavas, P.. - 328:(2025), pp. 313-317. [10.3233/SHTI250726]
PEDRO: A Peer-to-Peer Support Platform for Adverse Drug Reaction Management in Patients with CLL
Scarfo' L.;Ghia P.;
2025-01-01
Abstract
Chronic Lymphocytic Leukemia (CLL) treatment often leads to adverse drug reactions (ADRs) and drug-drug interactions (DDIs), significantly impacting patients’ quality of life (QoL). To address the challenges in managing ADRs/DDIs, the PEDRO platform was developed to enhance communication between healthcare professionals (HCPs) managing patients with CLL in real-world healthcare settings and experts with significant research profiles in CLL. This paper presents the PEDRO platform built to provide a secure, scalable, and user-friendly solution for peer-to-peer (P2P) support in ADR/DDI management.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
